Rocket Pharmaceuticals has raised $180 million through the sale of its Rare Pediatric Disease Priority Review Voucher, extending its cash runway into the second quarter of 2028. The voucher was awarded following the FDA's accelerated approval of KRESLADI, the company's gene therapy for a rare paediatric disease. The proceeds will support Rocket's cardiovascular gene therapy pipeline, which includes three clinical-stage programmes targeting major inherited cardiomyopathy subtypes: Danon disease, PKP2-associated arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy. These conditions collectively affect over 100,000 patients in the US and EU. The commercial-stage biotechnology company, which trades on Nasdaq under ticker RCKT, maintains proprietary AAV manufacturing capabilities and multi-year efficacy and safety data in cardiac gene therapy.

Rocket Pharmaceuticals receives FDA approval for KRESLADI gene therapy. Alexandra Moore Published Mar 30, 2026 - 04:18 Smallest Font Largest Font Rocket Pharmaceuticals recently announced a significant regulatory achievement, as the U.S. Food and Drug Administration (FDA) granted approval for KRESLADI. This gene therapy targets a rare pediatric disorder, marking the company's inaugural marketed product and a pivotal regulatory success after an extended review process, as reported by Detik Finance. This approval is particularly notable as KRESLADI becomes the first FDA-sanctioned gene therapy for this specific condition. The development positions Rocket Pharmaceuticals to establish a commercial presence within the ultra-rare disease market. Beyond the product approval itself, Rocket Pharmaceuticals also secured a Rare Pediatric Disease Priority Review Voucher. This asset offers biotech companies a valuable monetization opportunity. Management is actively exploring various strategic options for the voucher to bolster the company's financial flexibility. The company further stated its intentions to make KRESLADI accessible to eligible patients across the United States. Rocket Pharmaceuticals has indicated a controlled, rather than widespread, commercial rollout for KRESLADI. Recent company disclosures describe a tailored commercial strategy designed to address the very limited patient population. Reuters previously reported that the launch is anticipated to commence through a select number of specialized treatment centers. As of December 31, 2025, Rocket Pharmaceuticals held $188.9 million in cash, cash equivalents, and investments. Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) operates as a biotechnology firm dedicated to developing genetic therapies for various rare disorders. Its research pipeline encompasses both lentiviral and AAV-based programs, which are aimed at addressing immunological and cardiovascular diseases.

Rocket Pharmaceuticals has received FDA accelerated approval for KRESLADI, a gene therapy for pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) without an available matched sibling donor for transplant. The approval is based on increased neutrophil CD18 and CD11a surface expression, with continued approval contingent on verification of clinical benefit. LAD-I is an ultra-rare genetic disease affecting approximately one in 100,000 to 200,000 live births in the US, with two-thirds classified as severe. Patients suffer from recurrent, life-threatening bacterial and fungal infections requiring frequent hospitalisation. The FDA granted Rocket a Rare Pediatric Disease Priority Review Voucher, which the company intends to monetise. KRESLADI is now available to eligible patients in the United States through www.KRESLADI.com.